For example, in a non-MRD iteration of a precursor antibody panel, CD13 and HLA-DR expression patterns have been extensively evaluated in our laboratory on CD34-positive myeloblasts, in normal controls, and in individuals with myeloid neoplasms [32]. The gene discussed is CD34; the disease is myeloid neoplasm.